产品应用： Ixazomib citrate (MLN9708, Ninlaro) 是 Ixazomib (MLN2238)的前体，Ixazomib (MLN2238) 是一种选择性的 20S proteasome 的口服生物利用抑制剂，可抑制胰凝乳蛋白酶样蛋白水解(β5)位点，其IC50值和Ki值分别为3.4 nM和为0.93 nM。Ixazomib (MLN2238) 还抑制caspase样(β1)和胰蛋白酶样(β2)的蛋白水解位点，IC50分别为31 nM和3500 nM。 Information Ixazomib citrate (MLN9708, Ninlaro) is a prodrug of Ixazomib (MLN2238), which is a selective, orally bioavailable inhibitor of20S proteasomethat inhibits the chymotrypsin-like proteolytic (β5) site with IC50 of 3.4 nM and Ki of 0.93 nM, respectively. Ixazomib (MLN2238) also inhibits caspase-like (β1) and trypsin-like (β2) proteolytic sites with IC50 of 31 nM and 3500 nM, respectively. Targets 20S proteasome β5 site (Cell-free assay); 20S proteasome β5 site (Cell-free assay); 20S proteasome β1 site (Cell-free assay); 20S proteasome β2 site (Cell-free assay) 0.93 nM(Ki); 3.4 nM; 31 nM; 3500 nM